en · de · es
aod-9604-notes.peptides4962.com › Wiki › Regulation And Detection Context — Reference Sheet

Regulation And Detection Context — Reference Sheet

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-05 · Wiki

Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.

Regulation and Detection Context

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Handling, Analysis, and Quality Control

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusProhibited in sportListed by WADA under peptide hormones
WADA classS2Peptide hormones, growth factors, related substances, and mimetics
Approved therapeutic useNot establishedClinical research did not lead to broad marketing approval
Common detection methodLC-MS/MSLiquid chromatography-tandem mass spectrometry
Sample preparationExtraction and enrichmentImmunoaffinity or solid-phase extraction may be used

Handling And Analytical Properties

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Related pages on this site

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Background from the literature

Moscow will gain a branch of the Hermitage Museum in 2024. Authorities have agreed on the final project, which will be executed by Hani Rashid, co-founder of the New York-based firm Asymptote Architecture. This firm handled the stock market building in Moscow, the World Business Center Solomon Tower in Busan, and the Strata Tower in Abu Dhabi.

Selenium and zinc are commonly referred to as antioxidant minerals, but these chemical elements have no antioxidant action themselves, but rather are required for the activity of antioxidant enzymes, such as glutathione reductase and superoxide dismutase.

==== Jasmonates ==== Jasmonates are important in responses to injury and intracellular signals. They induce apoptosis and protein cascade via proteinase inhibitor, have defense functions, and regulate plant responses to different biotic and abiotic stresses. Jasmonates also have the ability to directly act on mitochondrial membranes by inducing membrane depolarization via release of metabolites. Jasmonate derivatives (JAD) are also important in wound response and tissue regeneration in plant cells. They have also been identified to have anti-aging effects on human epidermal layer. It is suspected that they interact with proteoglycans (PG) and glycosaminoglycan (GAG) polysaccharides, which are essential extracellular matrix (ECM) components to help remodel the ECM. The discovery of JADs on skin repair has introduced newfound interest in the effects of these plant hormones in therapeutic medicinal application.

== Further reading == Zachara, Natasha; Akimoto, Yoshihiro; Hart, Gerald W. (2015), Varki, Ajit; Cummings, Richard D.; Esko, Jeffrey D.; Stanley, Pamela (eds.), "The O-GlcNAc Modification", Essentials of Glycobiology (3rd ed.), Cold Spring Harbor Laboratory Press, PMID 28876858.

Decorative dried flower producer/growers and wholesalers hand-pick the decorative mature seeded pods/heads with or without the stalks for use in floral decorative arrangements. These are then mechanically dried at high temperatures in large kilns to render insects dead and the seeds unviable, so that the harvest consists almost entirely of the dried flowered seeded pods/heads (for ease of transport, artificial stems are added afterwards, e.g. bird seed wreath making, floral arrangements and wedding boutonnières or arts/craft projects). The seeds used for this market are chosen for the size and shape of the mature poppy seed pod/head and not alkaloid content. Many varieties, strains, and cultivars of Papaver somniferum are in existence, and the alkaloid content can vary significantly.

Sources: en.wikipedia.org

Further detail

==== Hospitalized patients ==== Remdesivir was approved for medical use in the United States in October 2020. The US Food and Drug Administration (FDA) approved remdesivir based on the agency's analysis of data from three randomized, controlled clinical trials that included participants hospitalized with mild-to-severe COVID‑19. The FDA granted approval and reissued the revised EUA to Gilead Sciences Inc. The FDA approved remdesivir based primarily on evidence from three clinical trials (NCT04280705, NCT04292899, and NCT04292730) of 2043 hospitalized participants with COVID‑19. The trials were conducted at 226 sites in 17 countries including the United States. In November 2020, the World Health Organization (WHO) updated its guideline on therapeutics for COVID‑19 to include a conditional recommendation against the use of remdesivir, triggered by results from the WHO Solidarity trial. Meanwhile, the Public Health Agency of Canada's COVID‑19 Clinical Pharmacology Task Group recommended that remdesivir only be administered to hospitalized patients as part of a randomized controlled trial due to limited information on risks and benefits. In January 2022, the Canadian component of the WHO Solidarity Trial reported that in-hospital people with COVID‑19 treated with remdesivir had 17% lower relative risk of death (18.7% versus 22.6% death rates) and 47% reduced relative risk for needing oxygen and mechanical ventilation (8.0% versus 15.0%) compared to people receiving standard-of-care treatments.

=== Diabetes === Cellular uptake of glucose occurs in response to insulin signals, and glucose is subsequently broken down through glycolysis, lowering blood sugar levels. However, insulin resistance or low insulin levels seen in diabetes result in hyperglycemia, where glucose levels in the blood rise and glucose is not properly taken up by cells. Hepatocytes further contribute to this hyperglycemia through gluconeogenesis. Glycolysis in hepatocytes controls hepatic glucose production, and when glucose is overproduced by the liver without having a means of being broken down by the body, hyperglycemia results.

=== Civil operations === An inaugural service from Moscow to Tashkent was flown on December 26, 1980, but services-proper commenced after February 1, 1981. Aeroflot first operated the Il-86 on peak domestic routes. Foreign services began in June 1981 to Eastern Europe. Services to larger West European cities began with the winter timetable starting in October that year. Charter flights to European points followed, with services on high-density medium/long-range routes within the Soviet Union coming last. Although the Il-86 was a medium-range airliner, from 1982 Aeroflot put it into scheduled service from Moscow to Havana via Shannon and Gander, "perhaps with limited payload or with additional tankerage." Other scheduled long-range services flown by the type were to Buenos Aires, Montevideo and Lima, Rio de Janeiro and São Paulo, all via Sal, Cape Verde. After the collapse of the Soviet Union in 1991, national airlines emerged in the 15 successor republics. Il-86s serving with Aeroflot administrations ("Directorates") in these nations accrued to their airlines and many were traded. From April 2002, the European Union, the US and much of the rest of the world banned noisier aircraft, including the Il-86. On October 23, 2006, Aeroflot Deputy Director General Igor Desyatnichenko said that the Il-86 was to be withdrawn from service starting November 15 that year as it operated for just two or three months in the summer."

=== 5S-GlcNAc === Ac45S-GlcNAc is converted intracellularly into UDP-5S-GlcNAc, a substrate analogue inhibitor of OGT. UDP-5S-GlcNAc is not efficiently utilized as a donor sugar by OGT, possibly due to distortion of the pyranose ring by replacement of oxygen with sulfur. As other glycosyltransferases utilize UDP-GlcNAc as a donor sugar, UDP-5S-GlcNAc has some non-specific effects on cell-surface glycosylation.

Sources: en.wikipedia.org

Supporting material

=== Interactions === There were eight interactions identified by Mentha. The first one was UFSP2 which hydrolyzes the peptide bond at the C-term gly of UFM1, a ubiquitin-like modifier protein bound to a number of target proteins. The second one was HSCB which acts as a co-chaperone in iron-sulfur cluster assembly in mitochondria. The third was GRB2 which is an adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway. The fourth was CYLD which is a protease that cleaves Lys-63-linked polyubiquitin chains, controls regulation of cell survival, proliferation, and differentiation, and is required for normal cell cycle progress. The fifth was ATM which activates checkpoint signaling upon double strand breaks, apoptosis, and genotoxic stress. The sixth was FAM177A1, the function of which is unknown. The last two were THID2 and Q81kP6 which are both in bacillus anthracis.

Human Vapor (Japanese: ガス人間; Korean: 가스인간) is a 2026 science fiction crime thriller television series based on the 1960 tokusatsu film The Human Vapor by Ishirō Honda and Takeshi Kimura. A Japanese–South Korean co-production written by Yeon Sang-ho and Ryu Yong-jae and directed by Shinzo Katayama, the series stars Shun Oguri, Yu Aoi, Suzu Hirose, Kento Hayashi, Uta, and Yutaka Takenouchi. It is produced by Toho Studios and Wow Point, marking the first collaboration between Netflix and Toho, and was released on Netflix on July 2, 2026.

==== Distribution ==== Following the administration of fospropofol 12.5 mg/kg (the maximum recommended dose) loss of consciousness takes about four minutes, compared to one arm-brain circulation time with propofol 2.5 mg/kg (the maximum recommended dose).

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

How is AOD-9604 detected?

Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.

Does AOD-9604 have approved therapeutic uses?

No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

Network